Global Thyroid Cancer Diagnostics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Thyroid Cancer Diagnostics Market Analysis

The thyroid cancer diagnostics market is witnessing significant advancements in methods and technologies, enhancing early detection and accuracy in diagnosis. Innovations such as molecular diagnostics, next-generation sequencing (NGS) services, and fine-needle aspiration (FNA) biopsies with enhanced imaging capabilities are leading the field. NGS, for instance, allows for the detection of genetic mutations associated with thyroid cancers, enabling personalized treatment plans. FNA, now often coupled with ultrasound, provides precise sampling, minimizing the need for invasive procedures.

Technological advancements also extend to artificial intelligence (AI) and machine learning (ML), which are increasingly used to analyze large data sets and identify cancerous patterns, improving diagnostic accuracy and reducing the risk of misdiagnosis. Liquid biopsies are emerging as non-invasive alternatives that detect cancer biomarkers in blood samples, further simplifying the diagnostic process.

Market growth is driven by the rising prevalence of thyroid cancer, increasing demand for minimally invasive diagnostics, and growing awareness. With these innovations, the thyroid cancer diagnostics market is positioned for robust growth, improving patient outcomes and supporting a more personalized healthcare approach.

Thyroid Cancer Diagnostics Market Size

The global thyroid cancer diagnostics market size was valued at USD 7.50 billion in 2023 and is projected to reach USD 11.69 billion by 2031, with a CAGR of 5.70% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Thyroid Cancer Diagnostics Market Trends

“Increasing Adoption of Molecular Diagnostics”

A key trend in the thyroid cancer diagnostics market is the rise of molecular diagnostic techniques, which offer higher precision and early detection. Molecular diagnostics, such as gene expression profiling and next-generation sequencing, are helping clinicians distinguish between benign and malignant thyroid nodules more accurately than traditional methods. For instance, the ThyroSeq test by CBLPath employs next-generation sequencing to analyze gene mutations and identify cancerous nodules, reducing unnecessary surgeries. The high demand for early-stage diagnosis, along with patient preference for non-invasive procedures, is fueling the adoption of molecular diagnostics, thereby driving market growth. This trend is expected to enhance diagnostic efficiency and outcomes in thyroid cancer management.

Report Scope and Thyroid Cancer Diagnostics Market Segmentation

Thyroid Cancer Diagnostics Market Definition

Thyroid cancer diagnostics involve a series of tests to detect cancerous cells in the thyroid gland. This process typically begins with a physical exam and patient history review, followed by blood tests to measure thyroid function and hormone levels. Imaging techniques, such as ultrasound, help visualize the thyroid's size and detect any abnormal nodules. If nodules appear suspicious, a fine needle aspiration biopsy is performed to examine tissue samples under a microscope. In addition, molecular testing of biopsy samples can identify genetic mutations linked to thyroid cancer. These diagnostics ensure accurate detection, aiding timely treatment decisions and improving patient outcomes.

Thyroid Cancer Diagnostics Market Dynamics

Drivers

• Increasing Thyroid Cancer Incidence

The increasing global incidence of thyroid cancer has significantly driven the demand for diagnostic tools, expanding the market as more people undergo screening and monitoring. For instance, the American Cancer Society reports that thyroid cancer rates have risen steadily, especially in developed countries, partly due to enhanced detection and awareness. Many healthcare systems now prioritize early screening programs, leading to timely identification of nodules or tumors. Initiatives such as these encourage frequent thyroid cancer diagnostic tests, including ultrasounds and molecular assays, contributing to early detection and better outcomes. This awareness and proactive approach to screening directly fuel market expansion in thyroid cancer diagnostics.

• Rise in Personalized Medicine

The surge in personalized medicine is a key driver for the thyroid cancer diagnostics market, as it enables treatments customized to a patient’s genetic profile. This precision approach, which uses genetic markers to guide therapy, has elevated demand for specialized diagnostic tests to identify specific thyroid cancer mutations. For instance, in May 2024, GE Healthcare unveiled its innovative Revolution RT, a state-of-the-art radiation therapy computed tomography (CT) device solution. This cutting-edge technology aims to enhance imaging accuracy while optimizing simulation workflows. By improving precision in oncology care, Revolution RT is set to provide clinicians and patients with a more personalized treatment experience, thus positioning GE Healthcare favorably within the competitive medical imaging landscape.

Opportunities

• Telemedicine and Digital Health Platforms

The surge in telemedicine and digital health platforms is creating significant opportunities in thyroid cancer diagnostics. By offering remote consultation and diagnostic services, video telemedicine allows high-risk patients, particularly those in remote or underserved areas, to access specialized care more easily. For instance, patients with limited access to in-person diagnostic facilities can now connect with endocrinologists online for initial consultations, leading to early thyroid screening recommendations and follow-up diagnostics. Platforms such as Teladoc and Amwell enable seamless patient-doctor interactions, enhancing diagnostic accessibility. As a result, telemedicine not only expands market reach but also boosts early detection rates, driving demand for thyroid cancer diagnostic tools.

• Increasing Prevalence of Genetic Testing

The increasing prevalence of genetic testing for hereditary predispositions to thyroid cancer presents a significant opportunity in the diagnostics market. Tests such as the ThyroSeq genomic sequencing panel allow for the identification of specific genetic mutations linked to thyroid tumors, enhancing diagnostic accuracy. For instance, in April 2020, Veracyte, Inc. launched the Afirma Xpression Atlas (XA) test, a groundbreaking diagnostic tool capable of detecting novel and rare gene alterations through advanced RNA sequencing. This innovative test is particularly promising in the field of thyroid cancer diagnostics, as it can significantly aid clinicians in making informed decisions regarding targeted therapies. The Afirma XA test is poised to improve patient outcomes by facilitating personalized treatment approaches.

Restraints/Challenges

• High Cost of Advanced Diagnostic Technologies

The high cost of advanced diagnostic technologies significantly hinders the thyroid cancer diagnostics market. Developing and implementing sophisticated tools such as molecular testing and advanced imaging techniques demand substantial financial investment, which poses a barrier for many healthcare providers. This financial burden is particularly pronounced in low-resource settings, where access to cutting-edge diagnostics is limited. As a result, the inability to utilize these technologies can lead to delayed diagnoses and treatment, ultimately impacting patient outcomes. Furthermore, the high costs deter healthcare systems from adopting innovative solutions, thereby stifling market growth and perpetuating disparities in access to effective thyroid cancer diagnostics.   

• Competition from Alternative Diagnostic Methods

The competition from alternative diagnostic methods poses a significant challenge for the thyroid cancer diagnostics market. Emerging technologies, particularly AI-driven diagnostics and non-invasive techniques, offer faster and potentially more accurate results, attracting both healthcare providers and patients. As these innovative methods gain traction, traditional diagnostic approaches, such as fine needle aspiration biopsies and histopathological evaluations, may experience reduced adoption rates. This shift can lead to decreased demand for established diagnostic tests, disrupting market dynamics and potentially causing financial strain on companies reliant on conventional methods. The resulting competition intensifies the pressure on traditional diagnostic approaches to demonstrate their value and efficacy in a rapidly evolving landscape.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Thyroid Cancer Diagnostics Market Scope

The market is segmented on the basis of product type, test type, cancer type, stages, age group, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Instruments
• Consumables
• Accessories

 Test Type

• Imaging Test
• Biopsy
• Blood Test
• Others

 Cancer Type

• Papillary Carcinoma
• Follicular Carcinoma
• Others

Stages

• Stage I
• Stage II
• Stage III
• Stage IV

 Age Group

• Below 21
• 21-29
• 30-65
• 65 and Above

 End User

• Hospital
• Associated Labs
• Independent Diagnostic Laboratories
• Diagnostic Imaging Centers
• Cancer Research Institutes
• Others

 Distribution Channel

• Direct Tender
• Retail Sales

Thyroid Cancer Diagnostics Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product type, test type, cancer type, stages, age group, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, U.A.E, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)

North America is expected to dominate the thyroid cancer diagnostics market, driven by increasing incidences of thyroid nodules and cancer. Enhanced awareness, advanced diagnostic technologies, and supportive healthcare policies will contribute to sustained market growth throughout the forecast period.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Thyroid Cancer Diagnostics Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Thyroid Cancer Diagnostics Market Leaders Operating in the Market Are:

• Canon Inc. (Japan)
• FUJIFILM Holdings Corporation (Japan)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Quest Diagnostics Incorporated (U.S.)
• Illumina (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• Thermo Fisher Scientific Inc. (U.S.)
• Siemens Healthcare GmbH (Germany)
• Abbott (U.S.)
• General Electric Company (U.S.)
• BD (U.S.)
• QIAGEN (Netherlands)
• DIASORIN S.P.A. (Italy)
• Merck KGaA (Germany)
• Hologic (U.S.)
• Myriad Genetics Inc. (U.S.)
• BIOMERIEUX (France)
• FONAR Corp. (U.S.)
• Time Medical Holding (Hong Kong)
• PlexBio (Taiwan)
• MinFound Medical Systems Co., Ltd (China)
• Medonica Co. LTD (South Korea)
• Beijing O&D Biotech Co., Ltd. (China)
• SternMed GmbH (Germany)

Latest Developments in Thyroid Cancer Diagnostics Market

• In May 2024, GE Healthcare unveiled its innovative Revolution RT, a state-of-the-art radiation therapy computed tomography (CT) solution. This cutting-edge technology aims to enhance imaging accuracy while optimizing simulation workflows. By improving precision in oncology care, Revolution RT is set to provide clinicians and patients with a more personalized treatment experience, thus positioning GE Healthcare favorably within the competitive medical imaging landscape
• In December 2020, Roche Holding AG received approval from the US FDA for its groundbreaking therapy, "Gavreto," aimed at treating patients with advanced mutant medullary thyroid cancer (MTC). This targeted therapy specifically addresses RET alterations, which play a crucial role in the development of medullary thyroid cancer. The approval not only expands treatment options for patients but also highlights Roche's commitment to advancing oncology therapeutics through innovative solutions
• In May 2020, Eli Lilly and Company achieved US FDA approval for Selpercatinib, a revolutionary drug designed for patients suffering from advanced RET-driven lung and thyroid cancer. This therapy specifically targets RET alterations, offering new hope to patients with these challenging conditions. By enhancing targeted treatment options, Selpercatinib reinforces Eli Lilly's position as a leader in the oncology space and addresses the urgent need for effective therapies
• In April 2020, Veracyte, Inc. launched the Afirma Xpression Atlas (XA) test, a groundbreaking diagnostic tool capable of detecting novel and rare gene alterations through advanced RNA sequencing. This innovative test is particularly promising in the field of thyroid cancer diagnostics, as it can significantly aid clinicians in making informed decisions regarding targeted therapies. The Afirma XA test is poised to improve patient outcomes by facilitating personalized treatment approaches

SKU-56963